Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dicobalt Edetate→

Dicobalt Edetate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
36499-65-7
Molecular formula
C10H12Co2N2O8
Molecular weight
406.08 g/mol
Drug class
Cobalt-based cyanide antidotecyanide complexation agent
Mechanism of action
Dicobalt edetate provides cobalt ions that bind cyanide to form a stable cobalt-cyanide complex, reducing free cyanide available to inhibit cytochrome c oxidase. Because unbound cobalt can cause severe cardiovascular toxicity, use is restricted to severe cyanide poisoning when the diagnosis is sufficiently certain.
Indications / reported uses
  • Emergency antidote for severe, confirmed or strongly suspected cyanide poisoning in jurisdictions where dicobalt edetate remains authorised; it is not suitable for empiric use when cyanide exposure is uncertain.

Sources: https://www.ema.europa.eu/en/documents/scientific-discussion/cyanokit-epar-scientific-discussion_en.pdf · https://pubmed.ncbi.nlm.nih.gov/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dicobalt Edetate Environmental Risk Assessment (ERA) (the Dicobalt Edetate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.